Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Guelar

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
HIV Medicine|August 5, 2015
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX studyE Pedrol, J M Llibre, M Tasias, et al.
HIV Clinical Trials|November 29, 2017
Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary teamE Molas, S Luque, A Retamero, et al.
AIDS (London, England)|December 5, 1997
Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitorsJ Mallolas, J Arrizabalaga, M Loncá, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|November 26, 2021
Impact of the COVID-19 pandemic: Community and hospital shared pharmaceutical care model. Satisfaction and acceptability of patients with HIV infection on antiretroviral treatmentM E Molas, H Knobel, O Ferrández, et al.
Medicina Clinica|October 13, 1990
[Encephalic toxoplasmosis in patients with the acquired immunodeficiency syndrome. A clinico-radiological study and the therapeutic results in 78 cases]J M González-Clemente, J M Miró, E Pedrol, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 1, 1997
[Prophylaxis secondary to retinitis by CMV in patients with AIDS: the efficacy of an intermittent schedule of 3 days/week]J Mallolas, J M Gatell, J L Gómez-Sirvent, et al.
HIV Medicine|April 28, 2007
Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA StudyJ Mallolas, Jl Blanco, P Labarga, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
HIV Medicine|August 5, 2015
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX studyE Pedrol, J M Llibre, M Tasias, et al.
HIV Clinical Trials|November 29, 2017
Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary teamE Molas, S Luque, A Retamero, et al.
AIDS (London, England)|December 5, 1997
Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitorsJ Mallolas, J Arrizabalaga, M Loncá, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|November 26, 2021
Impact of the COVID-19 pandemic: Community and hospital shared pharmaceutical care model. Satisfaction and acceptability of patients with HIV infection on antiretroviral treatmentM E Molas, H Knobel, O Ferrández, et al.
Medicina Clinica|October 13, 1990
[Encephalic toxoplasmosis in patients with the acquired immunodeficiency syndrome. A clinico-radiological study and the therapeutic results in 78 cases]J M González-Clemente, J M Miró, E Pedrol, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 1, 1997
[Prophylaxis secondary to retinitis by CMV in patients with AIDS: the efficacy of an intermittent schedule of 3 days/week]J Mallolas, J M Gatell, J L Gómez-Sirvent, et al.
HIV Medicine|April 28, 2007
Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA StudyJ Mallolas, Jl Blanco, P Labarga, et al.
Pageof 3